Purple Biotech Ltd
PPBT
$2.65
-$0.05-1.85%
NASDAQ
12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | ||
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | |
Total Other Revenue | -- | -- | -- | -- | |
Total Revenue | -- | -- | -- | -- | |
Cost of Revenue | 62.00K | -- | 196.00K | -- | |
Gross Profit | -62.00K | -- | -196.00K | -- | |
SG&A Expenses | 496.00K | 865.00K | 829.00K | 1.16M | |
Depreciation & Amortization | -- | -- | -- | -- | |
Other Operating Expenses | -- | -- | -- | -- | |
Total Operating Expenses | 1.02M | 3.26M | 6.27M | 5.75M | |
Operating Income | -1.02M | -3.26M | -6.27M | -5.75M | |
Income Before Tax | -415.00K | -2.42M | -4.86M | -5.06M | |
Income Tax Expenses | -- | -- | -- | -- | |
Earnings from Continuing Operations | -415.00K | -2.42M | -4.86M | -5.06M | |
Earnings from Discontinued Operations | -- | -- | -- | -- | |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
Minority Interest in Earnings | 5.00K | 10.00K | 31.00K | 19.00K | |
Net Income | -410.00K | -2.41M | -4.83M | -5.04M | |
EBIT | -1.02M | -3.26M | -6.27M | -5.75M | |
EBITDA | -1.01M | -3.21M | -6.26M | -5.70M | |
EPS Basic | 0.00 | -0.01 | -0.02 | -4.61 | |
Normalized Basic EPS | 0.00 | -0.01 | -0.01 | -- | |
EPS Diluted | 0.00 | -0.01 | -0.02 | -4.61 | |
Normalized Diluted EPS | 0.00 | -0.01 | -0.01 | -- | |
Average Basic Shares Outstanding | 410.26M | 275.32M | 257.90M | 1.09M | |
Average Diluted Shares Outstanding | 410.26M | 275.32M | 257.90M | 1.09M | |
Dividend Per Share | -- | -- | -- | -- | |
Payout Ratio | -- | -- | -- | -- |